Literature DB >> 27090957

Killer Cell Immunoglobulin-Like Receptor-Ligand Matching and Outcomes after Unrelated Cord Blood Transplantation in Acute Myeloid Leukemia.

Vanderson Rocha1, Annalisa Ruggeri2, Stephen Spellman3, Tao Wang4, Ronald Sobecks5, Franco Locatelli6, Medhat Askar7, Gerard Michel8, William Arcese9, Anna Paola Iori10, Duncan Purtill11, Robert Danby12, Guillermo F Sanz13, Eliane Gluckman14, Mary Eapen15.   

Abstract

The effect of killer cell immunoglobulin-like receptor (KIR)-ligand matching on outcomes after unrelated cord blood (CB) transplantation was studied in 461 patients with acute myeloid leukemia, categorizing KIR ligand for HLA-C groups C1 and C2 and Bw4. Donor-recipient HLA matching considered allele-level matching at HLA-A, -B, -C, and -DRB1. Separate analyses were conducted for 6-7/8 HLA-matched and 3-5/8 HLA-matched transplants because HLA matching confounded KIR-ligand matching (ie, KIR-ligand mismatching was less likely with better HLA matching). All patients received single CB unit and myeloablative conditioning. There were no significant differences in nonrelapse mortality (NRM), relapse, and overall mortality by KIR-ligand match status. However, among recipients of 3-5/8 HLA-matched transplants, NRM (HR, 2.26; P = .008) and overall mortality (HR, 1.78; P = .008) but not relapse were higher with KIR-ligand mismatched (host-versus-graft direction) compared with KIR-ligand matched transplants. These data do not support selecting CB units based on KIR-ligand match status for transplants mismatched at 1 or 2 HLA loci. Although transplants mismatched at 3 or more HLA loci are not recommended, avoiding KIR-ligand mismatching in this setting lowers mortality risks.
Copyright © 2016 American Society for Blood and Marrow Transplantation. All rights reserved.

Entities:  

Keywords:  Acute leukemia; Cord blood; KIR ligand; Unrelated transplant

Mesh:

Substances:

Year:  2016        PMID: 27090957      PMCID: PMC4915071          DOI: 10.1016/j.bbmt.2016.04.007

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  36 in total

Review 1.  Estimation of failure probabilities in the presence of competing risks: new representations of old estimators.

Authors:  T A Gooley; W Leisenring; J Crowley; B E Storer
Journal:  Stat Med       Date:  1999-03-30       Impact factor: 2.373

2.  Activating KIR genes are associated with CMV reactivation and survival after non-T-cell depleted HLA-identical sibling bone marrow transplantation for malignant disorders.

Authors:  C Chen; M Busson; V Rocha; M-L Appert; V Lepage; N Dulphy; P Haas; G Socié; A Toubert; D Charron; P Loiseau
Journal:  Bone Marrow Transplant       Date:  2006-08-07       Impact factor: 5.483

3.  Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors.

Authors:  Sebastian Giebel; Franco Locatelli; Teresa Lamparelli; Andrea Velardi; Stella Davies; Guido Frumento; Rita Maccario; Federico Bonetti; Jerzy Wojnar; Miryam Martinetti; Francesco Frassoni; Giovanna Giorgiani; Andrea Bacigalupo; Jerzy Holowiecki
Journal:  Blood       Date:  2003-04-10       Impact factor: 22.113

4.  Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value.

Authors:  Loredana Ruggeri; Antonella Mancusi; Marusca Capanni; Elena Urbani; Alessandra Carotti; Teresa Aloisi; Martin Stern; Daniela Pende; Katia Perruccio; Emanuela Burchielli; Fabiana Topini; Erika Bianchi; Franco Aversa; Massimo F Martelli; Andrea Velardi
Journal:  Blood       Date:  2007-03-19       Impact factor: 22.113

5.  HLA-C-dependent prevention of leukemia relapse by donor activating KIR2DS1.

Authors:  Jeffrey M Venstrom; Gianfranco Pittari; Ted A Gooley; Joseph H Chewning; Stephen Spellman; Michael Haagenson; Meighan M Gallagher; Mari Malkki; Effie Petersdorf; Bo Dupont; Katharine C Hsu
Journal:  N Engl J Med       Date:  2012-08-30       Impact factor: 91.245

6.  Missing KIR ligands are associated with less relapse and increased graft-versus-host disease (GVHD) following unrelated donor allogeneic HCT.

Authors:  Jeffery S Miller; Sarah Cooley; Peter Parham; Sherif S Farag; Michael R Verneris; Karina L McQueen; Lisbeth A Guethlein; Elizabeth A Trachtenberg; Michael Haagenson; Mary M Horowitz; John P Klein; Daniel J Weisdorf
Journal:  Blood       Date:  2007-02-22       Impact factor: 22.113

7.  Determinants of antileukemia effects of allogeneic NK cells.

Authors:  Wing Leung; Rekha Iyengar; Victoria Turner; Peter Lang; Peter Bader; Paul Conn; Dietrich Niethammer; Rupert Handgretinger
Journal:  J Immunol       Date:  2004-01-01       Impact factor: 5.422

8.  Improved survival with inhibitory killer immunoglobulin receptor (KIR) gene mismatches and KIR haplotype B donors after nonmyeloablative, HLA-haploidentical bone marrow transplantation.

Authors:  Heather J Symons; M Sue Leffell; Nancy D Rossiter; Marianna Zahurak; Richard J Jones; Ephraim J Fuchs
Journal:  Biol Blood Marrow Transplant       Date:  2009-12-02       Impact factor: 5.742

9.  The impact of donor KIR and patient HLA-C genotypes on outcome following HLA-identical sibling hematopoietic stem cell transplantation for myeloid leukemia.

Authors:  Mark A Cook; Donald W Milligan; Christopher D Fegan; Philip J Darbyshire; Premini Mahendra; Charles F Craddock; Paul A H Moss; David C Briggs
Journal:  Blood       Date:  2003-09-22       Impact factor: 22.113

10.  Negative effect of KIR alloreactivity in recipients of umbilical cord blood transplant depends on transplantation conditioning intensity.

Authors:  Claudio G Brunstein; John E Wagner; Daniel J Weisdorf; Sarah Cooley; Harriet Noreen; Juliet N Barker; Todd DeFor; Michael R Verneris; Bruce R Blazar; Jeffrey S Miller
Journal:  Blood       Date:  2009-03-27       Impact factor: 22.113

View more
  10 in total

Review 1.  Can we make a better match or mismatch with KIR genotyping?

Authors:  Rohtesh S Mehta; Katayoun Rezvani
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2016-12-02

Review 2.  Optimal Practices in Unrelated Donor Cord Blood Transplantation for Hematologic Malignancies.

Authors:  Juliet N Barker; Joanne Kurtzberg; Karen Ballen; Michael Boo; Claudio Brunstein; Corey Cutler; Mitchell Horwitz; Filippo Milano; Amanda Olson; Stephen Spellman; John E Wagner; Colleen Delaney; Elizabeth Shpall
Journal:  Biol Blood Marrow Transplant       Date:  2017-03-06       Impact factor: 5.742

Review 3.  Graft predominance after double umbilical cord blood transplantation: a review.

Authors:  Jan J Cornelissen; Burak Kalin; Cor H J Lamers
Journal:  Stem Cell Investig       Date:  2017-05-26

4.  Selection of allogeneic hematopoietic cell transplant donors to optimize natural killer cell alloreactivity.

Authors:  Brian C Shaffer; Katharine C Hsu
Journal:  Semin Hematol       Date:  2020-11-07       Impact factor: 3.851

5.  Natural Killer Cell Alloreactivity Predicted By Killer Cell Immunoglobulin-Like Receptor Ligand Mismatch Does Not Impact Engraftment in Umbilical Cord Blood and Haploidentical Stem Cell Transplantation.

Authors:  Folashade Otegbeye; Marcelo A Fernandez Vina; Tao Wang; Yung-Tsi Bolon; Aleksandr Lazaryan; Amer Beitinjaneh; Vijaya Raj Bhatt; Paul Castillo; Steven G E Marsh; Gerhard C Hildebrandt; Amer Assal; Valerie I Brown; Jingmei Hsu; Stephen Spellman; Marcos de Lima; Stephanie J Lee
Journal:  Transplant Cell Ther       Date:  2022-05-26

Review 6.  NK cell therapy for hematologic malignancies.

Authors:  Rohtesh S Mehta; Brion Randolph; May Daher; Katayoun Rezvani
Journal:  Int J Hematol       Date:  2018-01-27       Impact factor: 2.490

7.  Patients Lacking a KIR-Ligand of HLA Group C1 or C2 Have a Better Outcome after Umbilical Cord Blood Transplantation.

Authors:  Carmen Martínez-Losada; Carmen Martín; Rafael Gonzalez; Bárbara Manzanares; Estefania García-Torres; Concha Herrera
Journal:  Front Immunol       Date:  2017-07-13       Impact factor: 7.561

Review 8.  Reduction of Relapse after Unrelated Donor Stem Cell Transplantation by KIR-Based Graft Selection.

Authors:  Silke Heidenreich; Nicolaus Kröger
Journal:  Front Immunol       Date:  2017-02-08       Impact factor: 7.561

Review 9.  The Biological Role and Therapeutic Potential of NK Cells in Hematological and Solid Tumors.

Authors:  Rodion A Velichinskii; Maria A Streltsova; Sofya A Kust; Alexander M Sapozhnikov; Elena I Kovalenko
Journal:  Int J Mol Sci       Date:  2021-10-21       Impact factor: 5.923

10.  KIR B donors improve the outcome for AML patients given reduced intensity conditioning and unrelated donor transplantation.

Authors:  Daniel Weisdorf; Sarah Cooley; Tao Wang; Elizabeth Trachtenberg; Cynthia Vierra-Green; Stephen Spellman; Jennifer A Sees; Ashley Spahn; Jenny Vogel; Todd A Fehniger; Ann E Woolfrey; Steven M Devine; Maureen Ross; Edmund K Waller; Ronald M Sobecks; Joseph McGuirk; Betul Oran; Sherif S Farag; Tsiporah Shore; Koen Van Besien; Steven G E Marsh; Lisbeth A Guethlein; Peter Parham; Jeffrey S Miller
Journal:  Blood Adv       Date:  2020-02-25
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.